Remix Therapeutics To Participate In Upcoming Investor Conferences
- Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the 21st Annual Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at 10:15 a.m. ET in Boston. Remix management will participate in 1x1 meetings at the Cantor Global Healthcare Conference 2026 on Wednesday, September 9, 2026, in New York City.
About Remix Therapeutics
Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMasterTM technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, an RNA processing modulator in oncology, now being evaluated in a Phase 1/2 clinical study to treat acute myeloid leukemia (AML), and a Phase 1 clinical study in high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC).
Contacts:
Media:
Kara Stephens-Weaver
Precision AQ
...
Investors:
Will O'Connor
Precision AQ
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment